Form 4 for SMMT Summit Therapeutics Inc.
Accepted 2025-04-09 00:00:00 ET · period of report 2025-04-08 · accession 0001599298-25-000060 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DI | 2025-04-09 | 2025-04-08 | SMMT | Zanganeh Mahkam | Co-CEO, Dir, 10% | X - OptEx | $1.58 | +3.99M | 555.68M | +0.7% | +$6.30M |
| DI | 2025-04-09 | 2025-04-08 | SMMT | Zanganeh Mahkam | Co-CEO, Dir, 10% | X - OptEx | $0.00 | +3.99M | 0 | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-04-08 | X | A | 3,985,055 | $1.58 | 555,680,151 | I By Spouse | — | — | (F2) The Reporting Person disclaims beneficial ownership of these securities, except to the extent of her pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose. |
| 2 | Derivative | Warrant (right to buy) | 2025-04-08 | X | A | 3,985,055 | $0.00 | 0 | I By Spouse | $1.58 · 2020-06-24 to 2029-12-24 | 3,985,055 Common Stock | (F2) The Reporting Person disclaims beneficial ownership of these securities, except to the extent of her pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose. |